利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

27 条记录 (耗时 0.024 秒)

    DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN
    4.
    发明公开
    DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN 审中-公开
    磺烷基醚环糊精CONTAINING DPI制剂

    公开(公告)号：EP1755551A2

    公开(公告)日：2007-02-28

    申请号：EP05743067.0

    申请日：2005-04-22

    申请人： Cydex Inc.

    发明人： PIPKIN, James, D. ,  ZIMMERER, Rupert, O. ,  HICKEY, Anthony, J. ,  THOMPSON, Diane, O. ,  SMYTH, Hugh, D., C.

    IPC分类号： A61K9/00

    CPC分类号： A61K47/40 ,  A61K9/0075 ,  Y10T428/2982

    摘要： An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.

    INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID
    8.
    发明公开
    INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID 有权
    肾上腺皮质激素受体阻滞剂

    公开(公告)号：EP1732512A2

    公开(公告)日：2006-12-20

    申请号：EP05704917.3

    申请日：2005-01-03

    申请人： Cydex Inc.

    发明人： PIPKIN; James, D. ,  ZIMMERER, Rupert, O. ,  THOMPSON, Diane, O. ,  MOSHER, Gerold, L.

    IPC分类号： A61K9/12 ,  C08B37/16

    CPC分类号： A61K9/0078 ,  A61K9/0075 ,  A61K9/08 ,  A61K31/137 ,  A61K31/167 ,  A61K31/46 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58 ,  A61K47/40 ,  A61K47/6951 ,  B82Y5/00 ,  A61K31/16 ,  A61K2300/00 ,  A61K31/57 ,  A61K31/715

    摘要： An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.

    摘要翻译： 提供含有SAE-CD和皮质类固醇的可吸入单位剂量液体制剂。 该制剂适于用任何已知的雾化器通过雾化给予受试者。 制剂可以包含在试剂盒中。 制剂作为水溶液或浓缩组合物施用。 该制剂用于通过吸入施用皮质类固醇的改进的雾化系统。 配方中的SAE-CD显着提高了皮质类固醇（如布地奈德）的化学稳定性。 提供了通过吸入给药该制剂的方法。 制剂也可以通过常规鼻腔输送装置来施用。 通过将固体或液体（溶解）形式的SAE-CD与可吸入悬浮液的单位剂量制剂混合来制备制剂。

    CAPSULES CONTAINING AQUEOUS FILL COMPOSITIONS STABILIZED WITH DERIVATIZED CYCLODEXTRIN
    9.
    发明公开
    CAPSULES CONTAINING AQUEOUS FILL COMPOSITIONS STABILIZED WITH DERIVATIZED CYCLODEXTRIN 审中-公开
    与含水胶囊填充物组合物，具有衍生化环糊精稳定化

    公开(公告)号：EP1545477A1

    公开(公告)日：2005-06-29

    申请号：EP03759605.3

    申请日：2003-09-12

    申请人： Cydex Inc.

    发明人： THOMPSON, Diane, O. ,  ZIMMERER, Rupert, O. ,  PIPKIN, James, D.

    IPC分类号： A61K9/48 ,  A61K9/52

    CPC分类号： A61K31/724 ,  A61K9/4866 ,  A61K9/4891

    摘要： A capsule containing an aqueous fill composition that comprises water, a derivatized cyclodextrin, such as sulfoalkyl ether cyclodextrin (SAE-CD) or hydroxypropyl cyclodextrin (HPCD), optionally one or more active agents and optionally one or more excipients is stabilized from degradation, erosion, swelling or dissolution of its shell during storage. The derivatized cyclodextrin is present in an amount sufficient to reduce, eliminate or inhibit degradation, erosion, swelling and/or dissolution of the shell by water present in the fill composition. Alternatively, the derivatized cyclodextrin and another shell-stabilizing material together stabilize the shell from degradation, erosion, swelling and/or dissolution by water present in the fill composition. The derivatized cyclodextrin can reduce the water activity of the fill composition.

    USE OF SULFOALKYL ETHER CYCLODEXTRIN AS A PRESERVATIVE
    10.
    发明公开
    USE OF SULFOALKYL ETHER CYCLODEXTRIN AS A PRESERVATIVE 审中-公开
    USE磺烷基醚环糊精AS防腐剂

    公开(公告)号：EP1485110A1

    公开(公告)日：2004-12-15

    申请号：EP03723771.6

    申请日：2003-03-19

    申请人： Cydex Inc.

    发明人： MOSHER, Gerold, L. ,  PIPKIN, James, D. ,  ZIMMERER, Rupert, O. ,  FULK, CHristina, M. ,  THOMPSON, Diane, O.

    IPC分类号： A61K31/724 ,  A61K47/40

    CPC分类号： B82Y5/00 ,  A61K9/0019 ,  A61K31/05 ,  A61K31/724 ,  A61K47/40 ,  A61K47/6951 ,  Y02A50/473 ,  A61K2300/00

    摘要： An injectable formulation of a sedative hypnotic drug, such as the anesthetic drug propofol, that is pharmaceutically stable and demonstrates a reduced incidence of pain upon injection. The formulation of the present invention employs a sulfoalkyl ether cyclodextrin solubilizing and complexing excipient, such as CAPTISOL(R) cyclodextrin (sulfobutyl ether beta-cyclodextrin) to form a true aqueous solution and not a suspension. This formulation minimizes the allergic response and microbial contamination issues typically associated with propofol parenteral formulations. The present formulation may also reduce pain on injection as compared to the known emulsion type propofol formulations. The liquid formulation can be sterile filtered unlike emulsion-type formulations of sedative hypnotics. The liquid formulation can be lyophilized or otherwise dried to yield a solid formulation.